Compare · CERS vs WIT
CERS vs WIT
Side-by-side comparison of Cerus Corporation (CERS) and Wipro Limited (WIT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CERS and WIT operate in EDP Services (Technology), so they compete in similar markets.
- WIT is the larger of the two at $23.49B, about 45.1x CERS ($521.0M).
- Over the past year, CERS is up 93.3% and WIT is down 25.7% - CERS leads by 118.9 points.
- CERS has been more active in the news (12 items in the past 4 weeks vs 7 for WIT).
- WIT has more recent analyst coverage (23 ratings vs 4 for CERS).
- Company
- Cerus Corporation
- Wipro Limited
- Price
- -
- -
- Market cap
- $521.0M
- $23.49B
- 1M return
- -3.90%
- +13.67%
- 1Y return
- +93.28%
- -25.66%
- Industry
- EDP Services
- EDP Services
- Exchange
- NASDAQ
- NYSE
- IPO
- 1997
- News (4w)
- 12
- 7
- Recent ratings
- 4
- 23
Cerus Corporation
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
Wipro Limited
Wipro Limited operates as an information technology (IT), consulting, and business process services company worldwide. It operates through three segments: IT Services, IT Products, and India State Run Enterprise Services (ISRE). The IT Services segment offers IT and IT-enabled services, including digital strategy advisory, customer-centric design, technology consulting, IT consulting, custom application design, development, re-engineering and maintenance, systems integration, package implementation, infrastructure, analytics, business process, research and development, and hardware and software design services to enterprises. It serves customers in various industry sectors, such as healthcare and medical devices, consumer goods and life sciences, retail, transportation and services, communications, media and information services, technology products and platforms, banking, financial services and insurance, manufacturing, hi-tech, energy, and utilities. The IT Products segment provides a range of third-party IT products comprising enterprise platforms, networking solutions, software and data storage products, contact center infrastructure, enterprise security, IT optimization technologies, video solutions, and end-user computing solutions. It serves enterprises in various industries primarily in the India market, which comprise the government, defense, IT and IT-enabled services, telecommunications, manufacturing, utilities, education, and financial services sectors. The ISRE segment offers IT services to entities and/or departments owned or controlled by the Government of India and/or various Indian State Governments. Wipro Limited has a collaboration agreement with FEV Europe GmbH to develop and market software defined vehicles. The company was incorporated in 1945 and is based in Bengaluru, India.
Latest CERS
- Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress
- Director Bjerkholt Eric sold $53,180 worth of shares (20,454 units at $2.60), decreasing direct ownership by 7% to 261,679 units (SEC Form 4)
- Cerus Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Cerus Corporation Closes New Debt Facility of Up to $110 Million
- Cerus Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
- Director Lucena Ann was granted 60,000 shares, increasing direct ownership by 35% to 232,284 units (SEC Form 4)
- Director Bjerkholt Eric was granted 60,000 shares, increasing direct ownership by 27% to 282,133 units (SEC Form 4)
- Director Nachtsheim Jami K was granted 60,000 shares, increasing direct ownership by 29% to 268,362 units (SEC Form 4)
- Chief Operating Officer Jayaraman Vivek K sold $50,001 worth of shares (16,667 units at $3.00) as part of a pre-agreed trading plan, decreasing direct ownership by 1.00% to 1,656,707 units (SEC Form 4)
- Director Witney Frank was granted 60,000 shares, increasing direct ownership by 21% to 340,059 units (SEC Form 4)
Latest WIT
- METRO AG Achieves Major Milestone in Partnership with Wipro Towards AI-Led Transformation
- Amendment: SEC Form CB/A filed by Wipro Limited
- SEC Form 6-K filed by Wipro Limited
- Amendment: SEC Form CB/A filed by Wipro Limited
- SEC Form 6-K filed by Wipro Limited
- Wipro Annual Report 2026 on Form 20-F Available Online for ADS Holders
- SEC Form 20-F filed by Wipro Limited
- Amendment: SEC Form CB/A filed by Wipro Limited
- SEC Form 6-K filed by Wipro Limited
- SEC Form 6-K filed by Wipro Limited